Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

NCT ID: NCT02038920

Last Updated: 2019-12-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 157 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-28
• Study Completion Date: 2019-05-21

Brief Summary

This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.

Detailed Description

This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.

Conditions

Crohn's Disease

Keywords

Drug Therapy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Induction Phase: Vedolizumab, 300 mg

Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.

Group Type: EXPERIMENTAL

Vedolizumab

Intervention Type: DRUG

Vedolizumab IV injection

Induction Phase: Placebo

Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.

Group Type: PLACEBO_COMPARATOR

Vedolizumab placebo

Intervention Type: DRUG

Vedolizumab placebo-matching IV infusion

Maintenance Phase: Vedolizumab 300 mg

Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.

Group Type: EXPERIMENTAL

Vedolizumab

Intervention Type: DRUG

Vedolizumab IV injection

Maintenance Phase: Placebo

Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.

Group Type: PLACEBO_COMPARATOR

Vedolizumab placebo

Intervention Type: DRUG

Vedolizumab placebo-matching IV infusion

Maintenance Phase: Placebo Continuation

Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.

Group Type: PLACEBO_COMPARATOR

Vedolizumab placebo

Intervention Type: DRUG

Vedolizumab placebo-matching IV infusion

Open-Label: Vedolizumab 300 mg

Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.

Group Type: EXPERIMENTAL

Vedolizumab

Intervention Type: DRUG

Vedolizumab IV injection

Interventions

Vedolizumab

Vedolizumab IV injection

Intervention Type: DRUG

Vedolizumab placebo

Vedolizumab placebo-matching IV infusion

Intervention Type: DRUG

Other Intervention Names

MLN0002

Eligibility Criteria

Inclusion Criteria

1. In the opinion of the investigator, participants were capable of understanding and complying with protocol requirements

2. Participants or, when applicable, participants legally acceptable representative sign and date the informed consent form prior to initiation of any study procedures

3. Participants aged 15 to 80 years (inclusive) at the time of consent

4. A nonsterilized male participant who has a female partner of child-bearing potential has to agree to use adequate contraception during the period from the signing of informed consent to 6 months after the last dose of the study drug

5. A female participant of child-bearing potential (i.e., nonsterilized or whose last regular menses was within previous 2 years) who has a nonsterilized male partner has to agree to use adequate contraception during the period from the signing of informed consent to 6 months after the last dose of the study drug

6. Participants with a diagnosis of small-intestinal, large-intestinal, or small-/large-intestinal Crohn's disease (CD) established based on the Revised Diagnostic Criteria for Crohn's disease issued by Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2012) at least 3 months before the start of administration of study drug

7. Participants with baseline CDAI score of 220 to 450(inclusive) and meeting at least one of the followings:

• C-reactive protein (CRP) at screening test is above 0.30 mg/dL
• Participants with irregular or semicircular ulcers or multiple aphthae (10 or more) observed over an extensive area of the small or large intestine on endoscopy or imaging test within the 4 months before the start of administration of study drugs
• Participants with longitudinal ulcers or a cobblestone appearance observed in the small or large intestine on endoscopy or imaging test within 4 months before the start of administration of study drugs

8. In case of the participants who meet any of the following criteria; participants with ≥ 8-year history of extensive or limited colitis, participants aged ≥ 50 years, or participants with a first-degree family history of colon cancer, those whom the complication of colon cancer or dysplasia was ruled out by total colonoscopy at the start of study drug administration (or the results from total colonoscopy performed within 1 year before giving consent are available)

9. Participants meeting the criteria for treatment failure below with at least one of the following agents received within previous 5 year period before giving consent

1. Corticosteroids

• Resistance
• Dependence
• Intolerance

2. Immunomodulators (azathioprine, 6-mercaptopurine or methotrexate)

• Refractory
• Intolerance

3. Anti-tumor necrosis factor alpha (TNFα) antibodies

• Inadequate response
• Loss of response
• Intolerance

Exclusion Criteria

1. Participants with an evidence of or suspected abdominal abscess

2. Participants with a history of subtotal or total colectomy

3. Participants who have had a resection of the small intestine in at least 3 locations or have a diagnosis of short bowel syndrome

4. Participants with ileostomy, colostomy, or internal fistula, or severe intestinal stenosis

5. Participants who have a treatment history with natalizumab, efalizumab or rituximab

6. Participants who started 5-aminosalicylic acid oral drug or probiotics treatment, antimicrobials to treat Crohn's disease, or 30 mg/day or less of oral corticosteroids within 13 days before initiation of study drug administration. If these drugs were used within 14 days before initiation of study drug administration, the dosage must have been changed or their use discontinued within 13 days before the initiation of study drug administration

7. Participants who had received 5-aminosalicylic acid or corticosteroid enemas/suppositories, intravenous corticosteroid injections, or more than 30 mg/day of oral corticosteroids, medications for diarrhea-predominant irritable bowel syndrome, or Chinese herbal medicine for the treatment of Crohn's disease (e.g., Daikenchuto) within 13 days before initiation of study drug administration

8. Participants who had received azathioprine, 6-mercaptopurine, or methotrexate within 27 days before initiation of study drug administration. However, this shall not apply to participants who have received these drugs for 83 or more days before initiation of the study drug administration and continued the steady dose administration of the drugs for 27 or more days before initiation of the study drug administration

9. Participants who had received cyclosporin, tacrolimus, tofacitinib or any study drugs for treatment of ulcerative colitis within 27 days before initiation of the study drug administration

10. Participants who had received adalimumab within 27 days before initiation of study drug administration or any biological drugs other than adalimumab within 55 days before initiation of study drug administration. Topical administration (such as intraocular implantation for treatment of age-related maculopacy) is allowed

11. Participants who had received any live vaccinations within 27 days before initiation of study drug administration

12. Participants who had undergone intestinal resection within 27 days before initiation of study drug administration or those anticipated to require intestinal resection during the study

13. Participants who had received leukocytapheresis or granulocyte apheresis within 27 days before initiation of the study drug administration

14. Participants who had received intravenous hyperalimentation or total enteral nutrition within the 20 days before initiation of the study drug administration or participants who are fasted

15. Participants who had received enteral nutrition at > 900 kcal/day or started enteral nutrition at <= 900 kcal/day within the 20 days before initiation of the study drug administration. Participants receiving 900 kcal/day or less of enteral nutrition for at least 21 days before initiation of the study drug administration whom these dosage was changed or the medications were discontinued within 20 days before initiation of the study drug administration

16. Participants who had been infected with Clostridium difficile, cytomegalovirus, or any other intestinal pathogen within 27 days before the first dose of the study drug

17. Participants with evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration

18. Participants with a history or an complication of dysplasia of the small or large intestine

19. Participants who were suspected to have enteritis other than CD

20. Participants who were hepatitis B surface (HBs) antigen-positive or hepatitis C virus (HCV) antibody-positive at the screening. Or participants who are hepatitis B core (HBc) antibodypositive or HBs antibody positive, even though HBs antigen-negative. However, this does not apply to participants who are only HBs antibody-positive due to hepatitis B virus (HBV) vaccination, HBV-DNA-negative, HCV antigen-negative, or HCV-RNA-negative

21. Participants who had an evidence of history of tuberculosis or a suspected history of tuberculosis (including those who have findings suggesting previous tuberculosis on chest imaging procedure at the screening). However, this does not apply to participants who had completed prophylactic isoniazid, or participants who had been receiving prophylactic isoniazid for more than 21 days before the first dose of the study drug (in the latter case, the screening period are allowed to extend up to 28 days to ensure at least 21-day prophylactic isoniazid and then the study treatment is allowed to start)

22. Participants who had positive T-SPOT test or QuantiFERON test at the screening

23. Participants who had a history or complication of identified congenital or acquire immunodeficiency syndrome (eg, not-classifiable immunodeficiency, human immunodeficiency virus [HIV] infection or organ transplantation)

24. Participants who had been affected by extraintestinal infection (eg, pneumonia, sepsis, active hepatitis or pyelonephritis) within 27 days before the first dose of the study drug

25. Participants who had a treatment history with MLN0002

26. Female participants who are lactating at the screening, or have positive urine pregnancy test either at the screening or baseline

27. Participants who had serious complications in the heart, lung, liver, kidney, metabolism, gastrointestinal system, urinary system, endocrine system or blood

28. Participants who had a history of a surgery requiring general anesthesia within 27 days before the first dose of the study drug, or with a schedule of a surgery requiring hospitalization during the study period

29. Participants who had a complication or a history of malignancy. However, this does not apply to the following participants:

• Participants who had a curative resection of localized skin basal cell carcinoma or have completed curative radiotherapy
• Participants who had not experienced recurrence for more than 1 year since completion of a curative resection or curative radiotherapy for skin squamous cell carcinoma
• Participants who had not experienced recurrence for more than 3 years since completion of a curative resection or curative radiotherapy for intraepithelial carcinoma of uterine cervix For participants who had a substantially distant history of malignancy (eg, 10 years or longer without recurrence since treatment completion), the investigator and the sponsor had a discussion to decide eligibility on the basis of type of malignancy and treatment applied

30. Participants who had a history or a complication of the central nervous disorder, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.

31. Participants who had any subjective symptoms in the subjective PML checklist at the screening or baseline

32. Participants who had any of the following laboratory abnormalities at the screening;

• Hemoglobin ≤8 g/dL
• White blood cells ≤3,000/μL
• Lymphocytes ≤500/μL
• Platelets ≤100,000/μL or ≥1,200,000/μL
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3×upper limit of normal (ULN)
• Alkaline phosphatase (ALP) ≥3×ULN
• Creatinine ≥2×ULN

33. Participants who had a history or a complication of alcohol dependence or illicit drug use within one year before the first dose of the study drug

34. Participants who had a history or a complication of psychotic disorder that could obstruct compliance with the study procedures

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director Clinical Science

Role: STUDY_DIRECTOR

Takeda

Locations

Nagoya, Aichi-ken, Japan

Toyota, Aichi-ken, Japan

Hirosaki, Aomori, Japan

Abiko, Chiba, Japan

Kashiwa, Chiba, Japan

Sakura, Chiba, Japan

Matsuyama, Ehime, Japan

Chikushino-shi, Fukuoka, Japan

Kasuga, Fukuoka, Japan

Kitakyushu, Fukuoka, Japan

Takasaki, Gunma, Japan

Fukuyama, Hiroshima, Japan

Hatsukaichi, Hiroshima, Japan

Asahikawa, Hokkaido, Japan

Sapporo, Hokkaido, Japan

Tomakomai, Hokkaido, Japan

Akashi, Hyōgo, Japan

Nishinomiya, Hyōgo, Japan

Takamatsu, Kagawa-ken, Japan

Kamakura, Kanagawa, Japan

Kawasaki, Kanagawa, Japan

Sagamihara, Kanagawa, Japan

Yokohama, Kanagawa, Japan

Kochi, Kochi, Japan

Sendai, Miyagi, Japan

Kurashiki, Okayama-ken, Japan

Moriguchi, Osaka, Japan

Suita, Osaka, Japan

Tokorozawa, Saitama, Japan

Ōtsu, Shiga, Japan

Hamamatsu, Shizuoka, Japan

Shimotsuke, Tochigi, Japan

Adachi-ku, Tokyo, Japan

Bunkyo-ku, Tokyo, Japan

Chiyoda-ku, Tokyo, Japan

Minato-ku, Tokyo, Japan

Shinagawa-ku, Tokyo, Japan

Shinjuku-ku, Tokyo, Japan

Shūnan, Yamaguchi, Japan

Kofu, Yamanashi, Japan

Chiba, , Japan

Fukui, , Japan

Fukuoka, , Japan

Hiroshima, , Japan

Kagoshima, , Japan

Kumamoto, , Japan

Kyoto, , Japan

Nagasaki, , Japan

Niigata, , Japan

Okayama, , Japan

Okinawa, , Japan

Osaka, , Japan

Ōita, , Japan

Saga, , Japan

Saitama, , Japan

Wakayama, , Japan

Countries

Japan

References

Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res. 2021 Jan;19(1):95-105. doi: 10.5217/ir.2019.09167. Epub 2020 Jul 10.

Reference Type: DERIVED

PMID: 32635680 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

U1111-1150-2688

Identifier Type: OTHER

Identifier Source: secondary_id

JapicCTI-142402

Identifier Type: REGISTRY

Identifier Source: secondary_id

MLN0002/CCT-001

Identifier Type: -

Identifier Source: org_study_id